Crick
HomeTrialsGenesDrugs23andMeGraphBlogContact
  • Home
  • Trials
  • Genes
  • Drugs
  • 23andMe
  • Graph
  • Blog
  • Contact
Crick

An open-source clinical intelligence platform. Explore clinical trials, gene networks, and molecular structures using public data sources.

Data Sources

  • ClinicalTrials.gov
  • OpenTargets
  • ClinVar
  • PubChem

Links

  • Contact
  • Privacy

© 2026 Crick. All rights reserved.

Crick is for educational purposes only. Not medical advice.

Results for “Refractory Non-Hodgkin-Lymphoma”

Filters

Phase
Early Phase 1
Phase 1
Phase 2
Phase 3
Phase 4
Status
Recruiting
Active, Not Recruiting
Not Yet Recruiting
Completed
Enrolling by Invitation

Showing 20 of 0 results

Testing effectiveness (Phase 2)Ended earlyNCT02592876
What this trial is testing

Treatment Study of Denintuzumab Mafodotin (SGN-CD19A) Plus RICE Versus RICE Alone for Diffuse Large B-Cell Lymphoma

Who this might be right for
Lymphoma, B-cellLymphoma, Large B-Cell, DiffuseLymphoma, Follicular, Grade 3b+1 more
Seagen Inc. 81
Early research (Phase 1)Study completedNCT03939026
What this trial is testing

Safety and Efficacy of ALLO-501 Anti-CD19 Allogeneic CAR T Cells in Adults With Relapsed/Refractory Large B Cell or Follicular Lymphoma

Who this might be right for
Relapsed/Refractory Large B Cell LymphomaRelapsed/Refractory Follicular Lymphoma
Allogene Therapeutics 50
Very early researchLooking for participantsNCT04227015
What this trial is testing

CTA101 UCAR-T Cell Injection in Patients With Relapsed or Refractory CD19+ B-line Hematological Malignancy

Who this might be right for
Acute Lymphoblastic LeukemiaNon-hodgkin Lymphoma
He Huang 72
Not applicableLooking for participantsNCT06788652
What this trial is testing

Patients With Relapsed/Refractory Mantle Cell Lymphoma Treated With Lisocabtagene Maraleucel in the Post-Marketing Setting

Who this might be right for
Mantle Cell Lymphoma (MCL)
Juno Therapeutics, Inc., a Bristol-Myers Squibb Company 300
Very early researchUnknownNCT06045585
What this trial is testing

JY231 Injection in the Treatment of Relapsed or Refractory B-cell Lymphoma

Who this might be right for
Relapsed or Refractory B-cell Lymphoma
Guangdong Second Provincial General Hospital 20
Testing effectiveness (Phase 2)Ended earlyNCT02282358
What this trial is testing

Study of Mocetinostat in Selected Patients With Mutations of Acetyltransferase Genes in Relapsed and Refractory Diffuse Large B-Cell Lymphoma and Follicular Lymphoma

Who this might be right for
LymphomaRelapsed and RefractoryDiffuse Large B-Cell Lymphoma and Follicular Lymphoma
Memorial Sloan Kettering Cancer Center 7
Not applicableNo Longer AvailableNCT01196208
What this trial is testing

A Treatment-Option Protocol to Provide Brentuximab Vedotin to Eligible Patients Completing Studies SGN35-005 or C25001

Who this might be right for
Disease, HodgkinLymphoma, Large-Cell, AnaplasticLymphoma, Non-Hodgkin+1 more
Seagen Inc.
Testing effectiveness (Phase 2)Active Not RecruitingNCT02790515
What this trial is testing

Provision of TCRγδ T Cells and Memory T Cells Plus Selected Use of Blinatumomab in Naïve T-cell Depleted Haploidentical Donor Hematopoietic Cell Transplantation for Hematologic Malignancies Relapsed or Refractory Despite Prior Transplantation

Who this might be right for
Acute Lymphoblastic Leukemia (ALL)Acute Myeloid Leukemia (AML)Myeloid Sarcoma+4 more
St. Jude Children's Research Hospital 170
Early research (Phase 1)Looking for participantsNCT04260022
What this trial is testing

Study of HQP1351 in Subjects With Refractory CML and Ph+ ALL

Who this might be right for
Leukemia, Myeloid, ChronicMyeloid LeukemiaChronic Myeloid Leukemia+2 more
Ascentage Pharma Group Inc. 242
Large-scale testing (Phase 3)Study completedNCT00002456
What this trial is testing

Graft-Versus-Host Disease Prevention in Treating Patients Who Are Undergoing Bone Marrow Transplantation

Who this might be right for
Graft Versus Host DiseaseLeukemiaLymphoma
Fred Hutchinson Cancer Center
Early research (Phase 1)Looking for participantsNCT07225439
What this trial is testing

Rituximab (Rtx) + Tafasitamab in Combination With Allogeneic NK Cells for Treatment of Relapsed/Refractory (r/r) B-cell Non-Hodgkin Lymphoma (NHL)

Who this might be right for
Non Hodgkin LymphomaB-cell Non Hodgkin LymphomaDiffuse Large B Cell Lymphoma+7 more
Paolo Caimi, MD 15
Testing effectiveness (Phase 2)Ended earlyNCT06018129
What this trial is testing

A First-in-human Trial of GEN3017 in Hodgkin Lymphoma and Non-Hodgkin Lymphoma

Who this might be right for
Classical Hodgkin LymphomaNon-Hodgkin Lymphoma
Genmab 9
Testing effectiveness (Phase 2)Active Not RecruitingNCT04984837
What this trial is testing

Study of Lacutamab in Peripheral T-cell Lymphoma

Who this might be right for
Peripheral T Cell LymphomaRelapse/Recurrence
The Lymphoma Academic Research Organisation 49
Testing effectiveness (Phase 2)Looking for participantsNCT05934513
What this trial is testing

GFH009 Monotherapy in Patients with Relapsed or Refractory Peripheral T-cell Lymphoma (PTCL)

Who this might be right for
Relapsed or Refractory Peripheral T-cell Lymphoma (PTCL)
Genfleet Therapeutics (Shanghai) Inc. 95
Testing effectiveness (Phase 2)Study completedNCT00381940
What this trial is testing

Bortezomib, Ifosfamide, and Vinorelbine Tartrate in Treating Young Patients With Hodgkin's Lymphoma That is Recurrent or Did Not Respond to Previous Therapy

Who this might be right for
Adult Lymphocyte Depletion Hodgkin LymphomaAdult Lymphocyte Predominant Hodgkin LymphomaAdult Mixed Cellularity Hodgkin Lymphoma+17 more
National Cancer Institute (NCI) 26
Testing effectiveness (Phase 2)Looking for participantsNCT06542250
What this trial is testing

Evaluate Safety, PK, PD and Efficacy of AZD5492, a T Cell-engaging Antibody Targeting CD20 in Subjects With R/R B-Cell Malignancies.

Who this might be right for
B-cell Malignancies
AstraZeneca 174
Testing effectiveness (Phase 2)Study completedNCT00156013
What this trial is testing

Clofarabine for Relapsed or Refractory T-Cell or B-Cell Non-Hodgkin Lymphoma (NHL)

Who this might be right for
Lymphoma, B-CellLymphoma, Non-Hodgkin
Oncology Specialists, S.C. 33
Testing effectiveness (Phase 2)Active Not RecruitingNCT03075696
What this trial is testing

A Dose Escalation Study of Glofitamab (RO7082859) as a Single Agent and in Combination With Obinutuzumab, Administered After a Fixed, Single Pre-treatment Dose of Obinutuzumab in Participants With Relapsed/Refractory B-cell Non-hodgkin's Lymphoma

Who this might be right for
Non-Hodgkin's Lymphoma
Hoffmann-La Roche 940
Testing effectiveness (Phase 2)Study completedNCT01562990
What this trial is testing

Phase Ib/II Study of the Efficacy and Safety of the R-CMC544/R-GEMOX Combination in Diffuse Lage B-cell Lymphoma at First or Second Relapse

Who this might be right for
Diffuse Large B-Cell Lymphoma
The Lymphoma Academic Research Organisation 11
Early research (Phase 1)Study completedNCT02071888
What this trial is testing

Study of the Glutaminase Inhibitor CB-839 in Hematological Tumors

Who this might be right for
Non-Hodgkin's Lymphoma (NHL)Multiple MyelomaWaldenstrom's Macroglobulinemia (WM)+2 more
Calithera Biosciences, Inc 25
Next Page